Westover Capital Advisors LLC Buys 841 Shares of Boston Scientific Corporation $BSX

Westover Capital Advisors LLC grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 6.1% during the second quarter, HoldingsChannel reports. The firm owned 14,579 shares of the medical equipment provider’s stock after purchasing an additional 841 shares during the quarter. Westover Capital Advisors LLC’s holdings in Boston Scientific were worth $1,566,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1248 Management LLC bought a new position in shares of Boston Scientific in the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific in the 1st quarter worth about $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Princeton Global Asset Management LLC bought a new stake in Boston Scientific during the second quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific in the second quarter worth about $37,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 1.0%

Boston Scientific stock opened at $101.71 on Tuesday. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The business’s fifty day moving average is $99.59 and its 200 day moving average is $102.55. The stock has a market capitalization of $150.78 billion, a PE ratio of 54.39, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on BSX. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. UBS Group increased their target price on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Robert W. Baird upped their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.